Uniquely lymphoma,
uniquely Canadian


Mission Statement

LFC is a registered Canadian charitable organization with a mission to overcome lymphoma and provide leadership by:

  • Increasing awareness within the public and health communities about lymphoma;
  • Educating Canadians about the signs and symptoms of lymphoma;
  • Supporting individuals and families touched by lymphoma;
  • Advocating for the best treatments and care for lymphoma patients;
  • Funding medical research to discover the cause and ultimately the cure for lymphoma.

Highlights of Current Initiatives

A number of initiatives are currently underway in support of LFC’s corporate mission. These include:

General Practitioner (GP) Education Program:

  • Delayed diagnosis for individuals is an issue and can affect the outcome for some patients.
  • LFC’s hope is that GP education on the signs and symptoms of lymphoma will mean patients will be diagnosed earlier. This program will be an online, accredited continuing medical education (CME) program.

Consistency of Care for Lymphoma Patients Nationwide:

  • Identifying gaps in care, treatment options, and related demographics and geography issues for lymphoma patients is an important step in understanding how to improve consistency of care across the nation. To this end, LFC is in the process of creating a Report Card on Lymphoma in Canada.
  • LFC is working with its Scientific Advisory Board and the medical community to develop National Lymphoma Treatment Guidelines to ensure consistent protocols for all lymphoma patients regardless of where they live in Canada.

Support for New Treatment Options

  • LFC is grateful to be able to participate in patient submissions to the pan-Canadian Oncology Drug Review (pCODR), and is currently working on the third submission this year. Through surveys sent across Canada, LFC has collected qualitative and quantitative data to help inform the submissions.
  • LFC, in collaboration with several stakeholders, was instrumental in obtaining Ontario Government approval for rituximab to be funded for relapsed refractory follicular lymphoma patients. Our advocacy work to support access to treatment across Canada continues as new treatment options are being developed.

Commitment to Research

  • LFC has supported lymphoma research in Canada since the organization began, and continues to support research through funding of two two-year research fellowships.
  • In 2012, thanks to a generous gift of gratitude, LFC will be providing two additional significant research grants to Princess Margaret Hospital and Odette Cancer Centre at Sunnybrook Health Sciences Centre.

Innovative Patient Support

  • The online community of “people helping people” includes shared stories as well as patient blogs featured at www.lymphoma.ca.
  • The website also includes information on third party events across Canada, and updates to the community through LFC’s newsletter, the LFC LEAFlet.

Increased Awareness

  • Increasing awareness of lymphoma, including signs and symptoms, as well as ensuring patients know about LFC and the support that is available to them is a priority for LFC.
  • Stay tuned for new awareness campaigns launching through 2012.

Expanded Resources Across Canada

  • LFC is growing!
  • Recent staff additions include a full-time Quebec Regional Coordinator and Marketing Communication Coordinator, with additional staff to be hired in Fall 2012.

LFC provides an annual summary of our activities and financials, available at www.lymphoma.ca.

Key Dates

LFC has a number of events in the coming months. Please visit www.lymphoma.ca for more information. Highlights include:

  • Golf tournament:
    Aug 21, 2012 at Eagle’s Nest Golf Club, Maple, ON
  • Ontario Health Care and Patient Symposium:
    September 29, 2012 in Toronto, ON
  • Quebec Health Care and Patient Symposium:
    November 12, 2012 in Montreal, QC

Scientific Advisory Board

LFC would like to thank the following Scientific Advisory Board members for their dedication, commitment and support of the organization:


Dr. Joe Connors, MD (Chair) – Clinical Professor, University of British Columbia; Chair, Lymphoma Tumour Group, British Columbia Cancer Agency

Dr. Isabelle Bence-Bruckler, MD FRCPC – Hematologist, Associate Professor of Medicine, Member, Blood and Marrow Transplant Program, Ottawa General Hospital Campus


Dr. Spencer Gibson, PhD – Associate Professor, Manitoba Institute of Cell Biology, Department of Biochemistry and Medical Genetics, University of Manitoba


Dr. Mary Gospodarowicz, MD FRCPC FRCR(Hon) – Professor and Chair, Department of Radiation Oncology, University of Toronto, Chief, Radiation Medicine Program, Princess Margaret Hospital


Dr. Kevin Imrie, MD FRCPC – Physician-in- Chief, Sunnybrook Health Sciences Centre, Vice-chair, Education, Department of Medicine, University of Toronto, Professor of Medicine, University of Toronto


Dr. Ralph M. Meyer, MD, FRCP(C) – Director of the National Cancer Institute of Canada (NCIC) Clinical Trials Group and Holder of the Edith Eisenhauer Chair in Clinical Cancer Research, Queen’s University

How to Help

There are many ways to help LFC. These include patient referrals, involvement in events, connecting with LFC on lymphoma-related activities and stories in your community, as well as through donations. Please contact LFC for more information on how to get involved.

For more information, please visit the LFC’s website at: www.lymphoma.ca
Charitable Business Number: 87346 1040 RR0001

These mutations are emerging targets for therapy and because the mutations are generally mutually exclusive, melanoma can be molecularly classified into distinct subtypes which will differ in the response to therapy. Melanoma is a heterogeneous disease and should no longer be treated as homogenous entity.

Download Journal


Canadian Perspectives


Sunil Verma, MD, MSEd, FRCPC

Dr. Sunil Verma is a medical oncologist and the Chair of Breast Medical Oncology at the Sunnybrook Odette Cancer Centre in Toronto, Ontario. He is also an Associate Professor at the University of Toronto. Dr. Verma completed his medical degree and postgraduate training in internal medicine and medical oncology at the University of Alberta. He completed a fellowship in breast cancer at the University of Toronto and a master’s degree in medical education at the University of Southern California. Dr. Verma is internationally recognized for his educational leadership and research in breast and lung cancers. He has led and created numerous innovative educational projects in oncology and won several teaching and mentoring awards. Dr. Verma’s research interests include reducing the toxicity of systemic treatment, developing novel therapies for breast and lung cancers, and medical education. He is the principal inves - tigator for many clinical trials in breast and lung cancers, including an international phase III trial in breast cancer, and has authored or co-authored articles appearing in publications such as the Journal of Clinical Oncology, Cancer, The Oncologist, and Lancet Oncology.


Douglas A. Stewart, BMSc, MD, FRCPC
Dr. Douglas A. Stewart is currently a pro - fessor in the Departments of Oncology and Medicine, and Chief of the Division of Hematology and Hematological Ma - lignancies at the University of Calgary. Since July 1994, he has been practising medical oncology at the Tom Baker Cancer Centre in Calgary, where he is a member of the Breast Cancer and Hematology Tumour Groups, Leader of the Hematology/Blood and Marrow Transplant Program, and Provincial Leader of the Hematology Tumour Team for the Alberta Health Services Cancer Care Program. His research interests focus on clinical trials involving hematological malignancies and hematopoietic stem cell transplantation. Dr. Stewart has authored over 80 peer-reviewed manuscripts and over 120 abstracts.

Investigator Commentaries


Kimberly L. Blackwell, MD

Dr. Kimberly Blackwell is a medical oncologist, Professor of Medicine, and Assistant Professor of Radiation Oncology at Duke University Medical Center in Durham, North Carolina, U.S. She is the Director of the Breast Cancer Program at the Duke Cancer Institute and serves on the national Scientific Advisory Board of the Susan G. Komen for the Cure. She received her undergraduate degree in bioethics at Duke University, and her medical degree at Mayo Clinic Medical School. Afterwards, Dr. Blackwell completed an internal medicine internship and residency, and a hematology-oncology fellowship at Duke University Medical School. In addition to maintaining an active clinical practice, she has served as a principal investigator on many clinical trials in breast cancer. Her research interests include breast cancer angiogenesis, breast cancer in younger women, endocrine therapy, and HER2-targeted therapy. Dr. Blackwell has authored or co-authored over 40 articles or book chapters appearing in journals such as Clinical Cancer Research, the Journal of Clinical Oncology, Cancer, Radiation Research, and Molecular Cancer Therapeutics. In the past year, she has reviewed for several grant committees and peer-reviewed journals.


Tony Mok, MD
Dr. Tony Mok studied medicine at the University of Alberta and subsequently completed his fellowship training at the Princess Margaret Hospital in Toronto. After practising oncology and internal medicine for seven years in Toronto, Dr. Mok became an Assistant Professor in the Department of Clinical Oncology at the Chinese University of Hong Kong in 1996. He became a full professor in 2007. He holds an honorary professorship at the Guangdong Provincial People’s Hospital in Guangdong, China, and a guest professorship at the Peking University School of Oncology. He is heavily involved in several professional societies and committees, including being President-elect of the International Association for the Study of Lung Cancer. Dr. Mok is the Associate Editor of several journals and has published over 130 articles in peer-reviewed journals.


Mathias J. Rummel, MD, PhD
Mathias J. Rummel is the head of the Department for Hematology at the Clinic for Hematology and Medical Oncology at the Justus-Liebig University-Hospital, Giessen, Germany. Professor Rummel studied medicine at J.W. Goethe University Hospital in Frankfurt, Germany, obtaining his licence to practice medicine in 1995. Following this, he completed his doctoral degree and residency, obtained board certification in internal medicine, and was awarded his PhD from J.W. Goethe University Hospital. Professor Rummel’s current research focuses on novel treatment approaches in hematological malignancies, most notably follicular and other indolent lymphomas as well as hairy cell leukemia and also immune thrombocytopenic purpura (ITP). He is the chair of the Study group indolent Lymphomas (StiL) and principal investigator of several ongoing clinical trials in leukemias, lymphomas, and ITP. He is actively involved in a number of professional scientific societies, he is a reviewer for a number of journals, and has several published book chapters and papers to his credit.


Barbara F. Eichhorst, MD
Dr. Eichhorst graduated from the University of Munich School of Medicine in 1997, having completed a doctoral thesis in the field of hematology that focused on evaluating the signal transduction pathways of Hodgkin cells. She became a consultant in internal medicine after finishing an internship at Klinikum Grosshadern in the Department of Internal Medicine III at the University of Munich. Shortly after its founding, Dr. Eichhorst became a leading member of the German CLL Study Group and has served as the group’s secretary since 2005. She has published several papers on the treatment of chronic lymphocytic leukemia (CLL) and has acted as principal investigator for several phase II and III clinical trials that evaluated treatment optimization in CLL. Dr. Eichhorst is currently an Associate Professor at the University of Cologne and a consultant in hematology and internal oncology at the University Hospital of Cologne.


Arnon Nagler, MD, MSc
Arnon Nagler is Professor of Medicine at the Tel Aviv University, Tel Aviv, Israel, and the Director of both the Division of Hematology and the Bone Marrow Transplantation and Cord Blood Bank at the Chaim Sheba Medical Center, Tel Hashomer, Israel. Dr. Nagler received his medical training at the Hebrew University-Hadassah Medical School, Jerusalem, Israel, specializing in hematology at the Rambam Medical Center, Haifa, Israel. He carried out a postdoctoral research fellowship in hematology and bone marrow transplantation at Stanford University Hospital in Palo Alto, California, U.S. Dr. Nagler has been working in the fields of bone marrow transplantation for hematological malignancies, including non-Hodgkin lymphoma, and hemato-oncology, for the last 20 years. In Israel, Dr. Nagler established the first public cord blood bank and performed the first cord blood transplantations from related and unrelated donors in genetic and malignant hematological disease. His main clinical interests include stem cells, bone marrow transplantation, hematological malignancies, cord blood biology, and adoptive cell-mediated immunotherapy. Dr. Nagler has written numerous articles, reviews, and chapters for peer-reviewed journals, and is the principal investigator for a number of clinical studies. He serves on the Editorial Board of several journals and is a Section Editor for Leukemia.


Michael Hallek, MD
Dr. Michael Hallek is Professor of Medicine, and Director and Chair of the Department of Internal Medicine I at the University of Cologne in Cologne, Germany, where he oversees internal medicine, hematology, hemostaseology, oncology, intensive care, infectious diseases, and immunology. From 1994–2005, Dr. Hallek was head of the Gene Therapy Program at the Gene Center of the University of Munich and of the Clinical Cooperation Group for Gene Therapy at the National Centre for Research on Environment and Health (GSF) in Munich. In 2007, Dr. Hallek was appointed Director of the Center of Integrated Oncology (CIO), the joint comprehensive cancer centre of the Universities of Cologne and Bonn. Since 1994, he has been Chair of the German CLL Study Group. Dr. Hallek is the principal investigator for the CLL-8 clinical trial.